Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report

Background: Carcinoma Ex-pleomorphic adenoma is a malignant transformation of the common benign neoplasm of the salivary glands, “pleomorphic adenoma.” Only two cases were ever reported with brain metastases, with absence of good evidence guiding management of such cases. Case Presentation: A 61-year-old woman presenting with facial paralysis was found to have carcinoma ex-pleomorphic adenoma of the parotid gland. Twenty months after local treatment, she developed brain metastases, treated with whole brain radiation therapy. The patient then had progressive intracranial disease after the end of radiation therapy in addition to the appearance of liver metastases. Pathology showed overexpression of HER2, so she was treated with Trastuzumab Emtansine (TDM1). Follow-up imaging revealed significant decrease in the number and size of the metastatic brain lesions in keeping with a good response to TDM1 treatment. Conclusion: Prognosis of metastatic carcinoma ex-pleomorphic adenoma is very poor, and there is no clear management for such cases. We present a case of carcinoma ex-pleomorphic adenoma with brain and liver metastases with a very good response to TDM1 treatment.

[1]  anonymous In Review , 2018 .

[2]  V. Miller,et al.  Significant and durable clinical benefit from trastuzumab in 2 patients with HER2‐amplified salivary gland cancer and a review of the literature , 2017, Head & neck.

[3]  A. Gabarrós,et al.  Brain metastasis of carcinoma ex pleomorphic adenoma of the parotid gland: case report and review of the literature , 2017, Acta Neurochirurgica.

[4]  Y. Yatabe,et al.  Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma , 2013, Case Reports in Oncology.

[5]  S. Komune,et al.  HER‐2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in‐situ hybridization study , 2012, Histopathology.

[6]  E. Szabo,et al.  Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine , 2010, Head & neck oncology.

[7]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[8]  D. DeLone,et al.  CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland. , 2006, AJNR. American journal of neuroradiology.

[9]  T. Sebo,et al.  Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases. , 2001, Human pathology.

[10]  R. Spiro,et al.  Malignant mixed tumor of salivary origin. A clinicopathologic study of 146 cases , 1977, Cancer.

[11]  R. Spiro,et al.  Malignant mixed tumor of salivary origin. A clinicopathologic study of 146 cases , 1977, Cancer.

[12]  Yueh Z. Lee,et al.  ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES. , 2016, Cancer treatment communications.

[13]  K. Hongo,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[14]  D. Gnepp Malignant mixed tumors of the salivary glands: a review. , 1993, Pathology annual.